
Sudhakar Katakam
Examiner (ID: 15718)
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1658, 1676, 1671, 1621 |
| Total Applications | 1810 |
| Issued Applications | 1243 |
| Pending Applications | 144 |
| Abandoned Applications | 465 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18497391
[patent_doc_number] => 20230220021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => CYCLIC PEPTIDE INHIBITORS OF PSD-95 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/000946
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000946
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000946 | CYCLIC PEPTIDE INHIBITORS OF PSD-95 AND USES THEREOF | Jun 10, 2021 | Pending |
Array
(
[id] => 18675114
[patent_doc_number] => 20230312697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/009408
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009408
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009408 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | Jun 8, 2021 | Pending |
Array
(
[id] => 18496166
[patent_doc_number] => 20230218718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS
[patent_app_type] => utility
[patent_app_number] => 18/009230
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8475
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009230
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009230 | THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS | Jun 6, 2021 | Pending |
Array
(
[id] => 18510101
[patent_doc_number] => 20230226201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/928879
[patent_app_country] => US
[patent_app_date] => 2021-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928879
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/928879 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | May 31, 2021 | Pending |
Array
(
[id] => 18552127
[patent_doc_number] => 20230250134
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => SARS-COV-2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/004545
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004545
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004545 | SARS-COV-2 inhibitors | May 24, 2021 | Pending |
Array
(
[id] => 17299461
[patent_doc_number] => 20210395300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/329670
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17329670
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/329670 | Peptidomimetics for the treatment of Norovirus infection | May 24, 2021 | Issued |
Array
(
[id] => 18612324
[patent_doc_number] => 20230279056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => MODULAR AND GENERALIZABLE BIOSENSOR PLATFORM BASED ON DE NOVO DESIGNED PROTEIN SWITCHES
[patent_app_type] => utility
[patent_app_number] => 17/999524
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41592
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999524
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999524 | MODULAR AND GENERALIZABLE BIOSENSOR PLATFORM BASED ON DE NOVO DESIGNED PROTEIN SWITCHES | May 24, 2021 | Pending |
Array
(
[id] => 19701501
[patent_doc_number] => 12195510
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Insulin conjugates
[patent_app_type] => utility
[patent_app_number] => 17/329558
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 33274
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17329558
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/329558 | Insulin conjugates | May 24, 2021 | Issued |
Array
(
[id] => 18612324
[patent_doc_number] => 20230279056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => MODULAR AND GENERALIZABLE BIOSENSOR PLATFORM BASED ON DE NOVO DESIGNED PROTEIN SWITCHES
[patent_app_type] => utility
[patent_app_number] => 17/999524
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41592
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999524
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999524 | MODULAR AND GENERALIZABLE BIOSENSOR PLATFORM BASED ON DE NOVO DESIGNED PROTEIN SWITCHES | May 24, 2021 | Pending |
Array
(
[id] => 18823948
[patent_doc_number] => 11839209
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Interaction between antimicrobial quaternary compounds and anionic surfactants
[patent_app_type] => utility
[patent_app_number] => 17/303189
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 34134
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 180
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17303189
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/303189 | Interaction between antimicrobial quaternary compounds and anionic surfactants | May 23, 2021 | Issued |
Array
(
[id] => 19418484
[patent_doc_number] => 20240294607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => RECOMBINANT PROTEINS BASED ON FIBRINOGEN
[patent_app_type] => utility
[patent_app_number] => 17/925551
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6013
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925551
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925551 | RECOMBINANT PROTEINS BASED ON FIBRINOGEN | May 19, 2021 | Pending |
Array
(
[id] => 19418484
[patent_doc_number] => 20240294607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => RECOMBINANT PROTEINS BASED ON FIBRINOGEN
[patent_app_type] => utility
[patent_app_number] => 17/925551
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6013
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925551
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925551 | RECOMBINANT PROTEINS BASED ON FIBRINOGEN | May 19, 2021 | Pending |
Array
(
[id] => 17082057
[patent_doc_number] => 20210277063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND
[patent_app_type] => utility
[patent_app_number] => 17/319346
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17692
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/319346 | Method for producing cyclized peptide having intramolecular S-S bond | May 12, 2021 | Issued |
Array
(
[id] => 18656254
[patent_doc_number] => 20230302145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => SURFACTANT PROTEIN C MIMICS DISPLAYING PATHOGEN- OR ALLERGEN-BINDING MOIETIES
[patent_app_type] => utility
[patent_app_number] => 17/998337
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998337 | SURFACTANT PROTEIN C MIMICS DISPLAYING PATHOGEN- OR ALLERGEN-BINDING MOIETIES | May 9, 2021 | Pending |
Array
(
[id] => 17052189
[patent_doc_number] => 20210261623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => THETA DEFENSIN ANALOGS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/314473
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314473
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314473 | THETA DEFENSIN ANALOGS AND METHODS OF USE | May 6, 2021 | Abandoned |
Array
(
[id] => 19165863
[patent_doc_number] => 11981751
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Method of controlling adhesion and polarization of macrophages by using nanobarcode
[patent_app_type] => utility
[patent_app_number] => 17/246403
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 8757
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246403
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/246403 | Method of controlling adhesion and polarization of macrophages by using nanobarcode | Apr 29, 2021 | Issued |
Array
(
[id] => 17213169
[patent_doc_number] => 20210346505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => Oral Formulations of Kappa Opioid Receptor Agonists
[patent_app_type] => utility
[patent_app_number] => 17/242678
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/242678 | Oral formulations of kappa opioid receptor agonists | Apr 27, 2021 | Issued |
Array
(
[id] => 18526353
[patent_doc_number] => 11713338
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Cyclic peptides multimers targeting a-4-b-7 integrin
[patent_app_type] => utility
[patent_app_number] => 17/234488
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 31196
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 742
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234488
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234488 | Cyclic peptides multimers targeting a-4-b-7 integrin | Apr 18, 2021 | Issued |
Array
(
[id] => 18347346
[patent_doc_number] => 20230135456
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => CELL-DERIVED VESICLES COMPRISING WILD-TYPE P53 PROTEIN FOR ANTIVIRAL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/918573
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918573
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/918573 | CELL-DERIVED VESICLES COMPRISING WILD-TYPE P53 PROTEIN FOR ANTIVIRAL THERAPY | Apr 12, 2021 | Pending |
Array
(
[id] => 18709165
[patent_doc_number] => 20230331777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => NOVEL PEPTOID COMPOUNDS THAT BIND TO CELL RECEPTOR ACE2 AND PREVENT VIRUS ENTRY INTO CELLS
[patent_app_type] => utility
[patent_app_number] => 18/015927
[patent_app_country] => US
[patent_app_date] => 2021-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015927
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015927 | NOVEL PEPTOID COMPOUNDS THAT BIND TO CELL RECEPTOR ACE2 AND PREVENT VIRUS ENTRY INTO CELLS | Apr 6, 2021 | Pending |